Immuneonco Biopharmaceuticals Announces New Clinical Trial Updates for IMM2510/AXN-2510 in First-Line NSCLC Treatment

Reuters

22 May

Immuneonco Biopharmaceuticals Announces New Clinical Trial Updates for IMM2510/AXN-2510 in First-Line NSCLC Treatment

ImmuneOnco Biopharmaceuticals (Shanghai) Co. Ltd. announced updates on the clinical trials of their investigational drug IMM2510/AXN-2510 in combination with chemotherapy for the treatment of first-line non-small cell lung cancer (NSCLC). The announcement, made on a voluntary basis, aims to inform shareholders and potential investors about the latest developments in the company's business activities. The company, in partnership with Instil Bio, Inc., is advancing the Phase 2 trial of IMM2510/AXN-2510. However, ImmuneOnco cautions that there is no guarantee of successful development or commercialization of the drug. Investors are advised to exercise caution and seek professional advice if needed. The financial details related to this announcement have not been audited.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief on May 22, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2537854917"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537854917\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2537854917?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-22 18:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537854917","market":"nz","top_or_hot":-1,"title":"Immuneonco Biopharmaceuticals Announces New Clinical Trial Updates for IMM2510/AXN-2510 in First-Line NSCLC Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Immuneonco Biopharmaceuticals Announces New Clinical Trial Updates for IMM2510/AXN-2510 in First-Line NSCLC Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ImmuneOnco Biopharmaceuticals (Shanghai) Co. Ltd. announced updates on the clinical trials of their investigational drug IMM2510/AXN-2510 in combination with chemotherapy for the treatment of first-line non-small cell lung cancer (NSCLC). The announcement, made on a voluntary basis, aims to inform shareholders and potential investors about the latest developments in the company's business activities. The company, in partnership with <a href=\"https://laohu8.com/S/TIL\">Instil Bio, Inc.</a>, is advancing the Phase 2 trial of IMM2510/AXN-2510. However, ImmuneOnco cautions that there is no guarantee of successful development or commercialization of the drug. Investors are advised to exercise caution and seek professional advice if needed. The financial details related to this announcement have not been audited.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief on May 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immuneonco Biopharmaceuticals Announces New Clinical Trial Updates for IMM2510/AXN-2510 in First-Line NSCLC Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmuneonco Biopharmaceuticals Announces New Clinical Trial Updates for IMM2510/AXN-2510 in First-Line NSCLC Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-22 18:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Immuneonco Biopharmaceuticals Announces New Clinical Trial Updates for IMM2510/AXN-2510 in First-Line NSCLC Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ImmuneOnco Biopharmaceuticals (Shanghai) Co. Ltd. announced updates on the clinical trials of their investigational drug IMM2510/AXN-2510 in combination with chemotherapy for the treatment of first-line non-small cell lung cancer (NSCLC). The announcement, made on a voluntary basis, aims to inform shareholders and potential investors about the latest developments in the company's business activities. The company, in partnership with <a href=\"https://laohu8.com/S/TIL\">Instil Bio, Inc.</a>, is advancing the Phase 2 trial of IMM2510/AXN-2510. However, ImmuneOnco cautions that there is no guarantee of successful development or commercialization of the drug. Investors are advised to exercise caution and seek professional advice if needed. The financial details related to this announcement have not been audited.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief on May 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nNDL1NChjy:1","article_id":"2537854917","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537854917","pubTimestamp":1747908578,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ImmuneOnco Biopharmaceuticals  Co. Ltd. announced updates on the clinical trials of their investigational drug IMM2510/AXN-2510 in combination with chemotherapy for the treatment of first-line non-small cell lung cancer . The announcement, made on a voluntary basis, aims to inform shareholders and potential investors about the latest developments in the company's business activities. The company, in partnership with Instil Bio, Inc., is advancing the Phase 2 trial of IMM2510/AXN-2510. However, ImmuneOnco cautions that there is no guarantee of successful development or commercialization of the drug. Investors are advised to exercise caution and seek professional advice if needed. The financial details related to this announcement have not been audited.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shoul","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Immuneonco生物制药宣布IMM2510/AXN-2510一线治疗非小细胞肺癌的新临床试验更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01541":0.9,"TIL":0.9},"content_text":"Immuneonco Biopharmaceuticals Announces New Clinical Trial Updates for IMM2510/AXN-2510 in First-Line NSCLC Treatment\n    \n\n        ImmuneOnco Biopharmaceuticals (Shanghai) Co. Ltd. announced updates on the clinical trials of their investigational drug IMM2510/AXN-2510 in combination with chemotherapy for the treatment of first-line non-small cell lung cancer (NSCLC). The announcement, made on a voluntary basis, aims to inform shareholders and potential investors about the latest developments in the company's business activities. The company, in partnership with Instil Bio, Inc., is advancing the Phase 2 trial of IMM2510/AXN-2510. However, ImmuneOnco cautions that there is no guarantee of successful development or commercialization of the drug. Investors are advised to exercise caution and seek professional advice if needed. The financial details related to this announcement have not been audited.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief on May 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}